المؤلفون: Abdallah, Nadine H., Lakshman, Arjun, Kumar, Shaji K., Cook, Joselle, Binder, Moritz, Kapoor, Prashant, Dispenzieri, Angela, Gertz, Morie A., Lacy, Martha Q., Hayman, Suzanne R., Buadi, Francis K., Dingli, David, Lin, Yi, Kourelis, Taxiarchis, Warsame, Rahma, Bergsagel, Leif, Rajkumar, S. Vincent

المصدر: Blood Cancer Journal ; volume 14, issue 1 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الوصف: The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013–2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase ( n = 71), 51 progressed by last follow-up; the MDEs included: bone lesions (37%), anemia (35%), hypercalcemia (8%), and renal failure (6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression (14%), bone pain (20%), and hospitalization/ED presentations due to MM complications/symptoms (4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.

الإتاحة: https://doi.org/10.1038/s41408-024-00980-5Test
https://www.nature.com/articles/s41408-024-00980-5.pdfTest
https://www.nature.com/articles/s41408-024-00980-5Test

المؤلفون: Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J, Rybicka-Ramos, Malwina, Norman, Aaron D, Tyczyńska, Agata, Chanock, Stephen J, Barington, Torben, Kumar, Shaji K, Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E, Suska, Anna, Haastrup, Eva K, Orlowski, Robert Z, Dudziński, Marek, Garcia-Sanz, Ramon, Kruszewski, Marcin, Martinez-Lopez, Joaquin, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja I, Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Collado, Pilar Garrido, Vogel, Ulla, Hofmann, Jonathan N, Petrini, Mario, Butrym, Aleksandra, Slager, Susan L, Ziv, Elad, Subocz, Edyta, Giles, Graham G, Andersen, Niels Frost, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A T, Zawirska, Daria, Ebbesen, Lene Hyldahl, Marques, Herlander, Gemignani, Federica, Dumontet, Charles, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J, Grzasko, Norbert, Waller, Rosalie G, Vachon, Celine, Canzian, Federico, Campa, Daniele

المساهمون: Dicanio, Marco, Giaccherini, Matteo, Clay-Gilmour, Alyssa, Macauda, Angelica, Sainz, Juan, Machiela, Mitchell J, Rybicka-Ramos, Malwina, Norman, Aaron D, Tyczyńska, Agata, Chanock, Stephen J, Barington, Torben, Kumar, Shaji K, Bhatti, Parveen, Cozen, Wendy, Brown, Elizabeth E, Suska, Anna, Haastrup, Eva K, Orlowski, Robert Z, Dudziński, Marek, Garcia-Sanz, Ramon, Kruszewski, Marcin, Martinez-Lopez, Joaquin, Beider, Katia, Iskierka-Jazdzewska, Elżbieta, Pelosini, Matteo, Berndt, Sonja I, Raźny, Małgorzata, Jamroziak, Krzysztof, Rajkumar, S Vincent, Jurczyszyn, Artur, Vangsted, Annette Juul, Collado, Pilar Garrido, Vogel, Ulla, Hofmann, Jonathan N, Petrini, Mario, Butrym, Aleksandra, Slager, Susan L, Ziv, Elad, Subocz, Edyta, Giles, Graham G, Andersen, Niels Frost, Mazur, Grzegorz, Watek, Marzena, Lesueur, Fabienne, Hildebrandt, Michelle A T, Zawirska, Daria, Ebbesen, Lene Hyldahl, Marques, Herlander, Gemignani, Federica, Dumontet, Charle, Várkonyi, Judit, Buda, Gabriele, Nagler, Arnon, Druzd-Sitek, Agnieszka, Wu, Xifeng, Kadar, Katalin, Camp, Nicola J, Grzasko, Norbert, Waller, Rosalie G, Vachon, Celine, Canzian, Federico, Campa, Daniele

مصطلحات موضوعية: genetic susceptibility, multiple myeloma, pleiotropy, pleiotropy scan, polymorphism, Human, Oncogene, Allele, Phenotype, Single Nucleotide, Genome-Wide Association Study, Genetic Predisposition to Disease, HSP40 Heat-Shock Protein, DNA-Binding Protein, RNA-Binding Protein

الوصف: Pleiotropy, which consists of a single gene or allelic variant affecting multiple unrelated traits, is common across cancers, with evidence for genome-wide significant loci shared across cancer and noncancer traits. This feature is particularly relevant in multiple myeloma (MM) because several susceptibility loci that have been identified to date are pleiotropic. Therefore, the aim of this study was to identify novel pleiotropic variants involved in MM risk using 28 684 independent single nucleotide polymorphisms (SNPs) from GWAS Catalog that reached a significant association (P < 5 x 10(-8)) with their respective trait. The selected SNPs were analyzed in 2434 MM cases and 3446 controls from the International Lymphoma Epidemiology Consortium (InterLymph). The 10 SNPs showing the strongest associations with MM risk in InterLymph were selected for replication in an independent set of 1955 MM cases and 1549 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and 418 MM cases and 147 282 controls from the FinnGen project. The combined analysis of the three studies identified an association between DNAJB4-rs34517439-A and an increased risk of developing MM (OR = 1.22, 95%CI 1.13-1.32, P = 4.81 x 10(-7)). rs34517439-A is associated with a modified expression of the FUBP1 gene, which encodes a multifunctional DNA and RNA-binding protein that it was observed to influence the regulation of various genes involved in cell cycle regulation, among which various oncogenes and oncosuppressors. In conclusion, with a pleiotropic scan approach we identified DNAJB4-rs34517439 as a potentially novel MM risk locus.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36082445; info:eu-repo/semantics/altIdentifier/wos/WOS:000862925500001; volume:152; issue:2; firstpage:239; lastpage:248; numberofpages:10; journal:INTERNATIONAL JOURNAL OF CANCER; https://hdl.handle.net/11568/1157424Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85139053286

الإتاحة: https://doi.org/10.1002/ijc.34278Test
https://hdl.handle.net/11568/1157424Test

المؤلفون: Facon, Thierry, Kumar, Shaji K, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, Perrot, Aurore, Weisel, Katja, Raje, Noopur, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Wang, Jianping, Rampelbergh, Rian Van, Uhlar, Clarissa M, Vermeulen, Jessica, Duran, Joana, Borgsten, Fredrik, Usmani, Saad Z

المساهمون: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, Janssen, Molecular Templates, Novartis, Roche-Genentech, Takeda, TeneoBio

المصدر: Future Oncology ; volume 19, issue 13, page 887-895 ; ISSN 1479-6694 1744-8301

الإتاحة: https://doi.org/10.2217/fon-2023-0082Test

المؤلفون: Richardson, Paul G., Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell, Karlin, Lionel, Benboubker, Lotfi, Voog, Eric, Yoon, Sung-Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Villarreal, Miguel, Twumasi-Ankrah, Philip, Labotka, Richard, Rifkin, Robert M., Lonial, Sagar, Kumar, Shaji K., Rajkumar, S. Vincent, Moreau, Philippe

المصدر: EJHAEM ; ISSN: 2688-6146

مصطلحات موضوعية: Medicine and Health Sciences, depth of response, ixazomib, multiple myeloma, response kinetics, LENALIDOMIDE, SURVIVAL, KINETICS, THERAPY

الوصف: Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months; n = 424) versus late responders (best confirmed response >4 months; n = 281). Newly diagnosed patients enrolled in TOURMALINE-MM2 receiving ixazomib-lenalidomide-dexamethasone (IRd) (n = 351) or placebo-Rd (n = 354) were evaluated post hoc. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months). Among patients with a PFS (n = 511) or DOR (n = 484) of >= 6 months who achieved >= PR, median PFS was prolonged among late versus early responders receiving IRd (59.7 vs. 17.9 months) or placebo-Rd (56.6 vs. 12.4 months), as was median DOR (IRd, NR vs. 20.9 months; placebo-Rd, 58.2 vs. 11.7 months). While the treatment paradigm for newly diagnosed MM is treatment to progression, our findings suggest slowness of response to a proteasome inhibitor-immunomodulatory drug-steroid combination is not a negative predictor of outcome.

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMRTest; http://hdl.handle.net/1854/LU-01HYZTXAMK5TTTJXXA7WKKQEMRTest; http://doi.org/10.1002/jha2.759Test; https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMR/file/01HYZTXHV49EQCFMJN7H2WFH32Test

الإتاحة: https://doi.org/10.1002/jha2.759Test
https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMRTest
http://hdl.handle.net/1854/LU-01HYZTXAMK5TTTJXXA7WKKQEMRTest
https://biblio.ugent.be/publication/01HYZTXAMK5TTTJXXA7WKKQEMR/file/01HYZTXHV49EQCFMJN7H2WFH32Test

المؤلفون: Clavero, Esther, Sanchez-Maldonado, José Manuel, Macauda, Angelica, Ter Horst, Rob, Marques, Maria Belém Sousa Sampaio, Jurczyszyn, Artur, Clay-Gilmour, Alyssa, Stein, Angelika, Hildebrandt, Michelle A. T., Weinhold, Niels, Buda, Gabriele, García-Sanz, Ramón, Tomczak, Waldemar, Vogel, Ulla, Jerez, Andrés, Zawirska, Daria, Wątek, Marzena, Hofmann, Jonathan N., Landi, Stefano, Spinelli, John J., Butrym, Aleksandra, Kumar, Abhishek, Martínez-López, Joaquín, Galimberti, Sara, Sarasquete, María Eugenia, Subocz, Edyta, Iskierka-Jażdżewska, Elzbieta, Giles, Graham G., Rybicka-Ramos, Malwina, Kruszewski, Marcin, Abildgaard, Niels, Verdejo, Francisco García, Sánchez Rovira, Pedro, da Silva Filho, Miguel Inacio, Kadar, Katalin, Razny, Małgorzata, Cozen, Wendy, Pelosini, Matteo, Jurado, Manuel, Bhatti, Parveen, Dudzinski, Marek, Druzd-Sitek, Agnieszka, Orciuolo, Enrico, Li, Yang, Norman, Aaron D., Zaucha, Jan Maciej, Reis, R. M., Markiewicz, Miroslaw, Rodríguez Sevilla, Juan José, Andersen, Vibeke, Jamroziak, Krzysztof, Hemminki, Kari, Berndt, Sonja I., Rajkumar, Vicent, Mazur, Grzegorz, Kumar, Shaji K., Ludovico, Paula, Nagler, Arnon, Chanock, Stephen J., Dumontet, Charles, Machiela, Mitchell J., Varkonyi, Judit, Camp, Nicola J., Ziv, Elad, Vangsted, Annette Juul, Brown, Elizabeth E., Campa, Daniele, Vachon, Celine M., Netea, Mihai G., Canzian, Federico, Försti, Asta, Sainz, Juan

مصطلحات موضوعية: Multiple myeloma, Autophagy, Genetic variants, Genetic susceptibility

الوصف: Functional data used in this project have been meticulously catalogued and archived in the BBMRI-NL data infrastructure (https://hfgp.bbmri.nlTest/, accessed on 12 February 2020) using the MOLGENIS open-source platform for scientific data. ; Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte hemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP corre lated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+ IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4 ) and circulating concentrations of interleukin (IL)-20 (p = ...

وصف الملف: application/pdf

العلاقة: PY20/01282; R01CA186646; U01CA249955; info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50026%2F2020/PT; info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F50026%2F2020/PT; NORTE-01-0145-FEDER-000055; https://www.mdpi.com/1422-0067/24/10/8500Test; https://hfgp.bbmri.nlTest/; Clavero, E.; Sanchez-Maldonado, J.M.; Macauda, A.; Ter Horst, R.; Sampaio-Marques, B.; Jurczyszyn, A.; Clay-Gilmour, A.; Stein, A.; Hildebrandt, M.A.T.; Weinhold, N.; et al. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. Int. J. Mol. Sci. 2023, 24, 8500. https://doi.org/10.3390/ijms24108500Test; https://hdl.handle.net/1822/85628Test

الإتاحة: https://doi.org/10.3390/ijms24108500Test
https://hdl.handle.net/1822/85628Test

المؤلفون: Muchtar, Eli, Dispenzieri, Angela, Wisniowski, Brendan, Palladini, Giovanni, Milani, Paolo, Merlini, Giampaolo, Schönland, Stefan, Veelken, Kaya, Hegenbart, Ute, Geyer, Susan M, Kumar, Shaji K, Kastritis, Efstathios, Dimopoulos, Meletios A, Liedtke, Michaela, Witteles, Ronald, Sanchorawala, Vaishali, Szalat, Raphael, Landau, Heather, Petrlik, Erica, Lentzsch, Suzanne, Coltoff, Alexander, Bladé, Joan, Cibeira, Maria Teresa, Cohen, Oliver, Foard, Darren, Wechalekar, Ashutosh, Gertz, Morie A

المصدر: Journal of Clinical Oncology , 41 (7) pp. 1393-1403. (2023)

الوصف: PURPOSE: Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide. PATIENTS AND METHODS: This retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth: cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival. RESULTS: 651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22% v 13.5% v 3.2%; P < .001). A deeper cardiac response was associated with a longer survival (5-year overall survival 93%, 79%, 65%, and 33% for CarCR, CarVGPR, CarPR, and CarNR, respectively; P < .001). Fixed time-point analyses and time-varying covariates Cox regression analysis, to minimize survivorship bias, affirmed the independent survival advantage of deeper cardiac responses. Four-level response performed better than two-level response as early as 12 months from therapy initiation. CONCLUSION: Graded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10158648/1/jco.22.00643.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10158648Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10158648/1/jco.22.00643.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10158648Test/

المؤلفون: Macauda, Angelica, Briem, Klara, Clay-Gilmour, Alyssa, Cozen, Wendy, Försti, Asta, Giaccherini, Matteo, Corradi, Chiara, Sainz, Juan, Niazi, Yasmeen, ter Horst, Rob, Li, Yang, Netea, Mihai G., Vogel, Ulla, Hemminki, Kari, Slager, Susan L., Varkonyi, Judit, Andersen, Vibeke, Iskierka-Jazdzewska, Elzbieta, Mártinez-Lopez, Joaquin, Zaucha, Jan, Camp, Nicola J., Rajkumar, S. Vincent, Druzd-Sitek, Agnieszka, Bhatti, Parveen, Chanock, Stephen J., Kumar, Shaji K., Subocz, Edyta, Mazur, Grzegorz, Landi, Stefano, Machiela, Mitchell J., Jerez, Andrés, Norman, Aaron D., Hildebrandt, Michelle A.T., Kadar, Katalin, Berndt, Sonja I., Ziv, Elad, Buda, Gabriele, Nagler, Arnon, Dumontet, Charles, Raźny, Malgorzata, Watek, Marzena, Butrym, Aleksandra, Grzasko, Norbert, Dudzinski, Marek, Rybicka-Ramos, Malwina, Matera, Eva Laure, García-Sanz, Ramón, Goldschmidt, Hartmut, Jamroziak, Krzysztof, Jurczyszyn, Artur, Clavero, Esther, Giles, Graham G., Pelosini, Matteo, Zawirska, Daria, Kruszewski, Marcin, Marques, Herlander, Haastrup, Eva, Sánchez-Maldonado, José Manuel, Bertsch, Uta, Rymko, Marcin, Raab, Marc Steffen, Brown, Elizabeth E., Hofmann, Jonathan N., Vachon, Celine, Campa, Daniele, Canzian, Federico

المصدر: Macauda , A , Briem , K , Clay-Gilmour , A , Cozen , W , Försti , A , Giaccherini , M , Corradi , C , Sainz , J , Niazi , Y , ter Horst , R , Li , Y , Netea , M G , Vogel , U , Hemminki , K , Slager , S L , Varkonyi , J , Andersen , V , Iskierka-Jazdzewska , E , Mártinez-Lopez , J , Zaucha , J , Camp , N J , Rajkumar , S V , Druzd-Sitek , A , Bhatti , ....

مصطلحات موضوعية: Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Multiple Myeloma/genetics, Polymorphism, Single Nucleotide

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/c792598c-52ac-4202-ac07-8ef690567d31Test

الإتاحة: https://doi.org/10.1038/s41375-023-02022-8Test
https://portal.findresearcher.sdu.dk/da/publications/c792598c-52ac-4202-ac07-8ef690567d31Test
https://findresearcher.sdu.dk/ws/files/244938452/Open_Access_Version.pdfTest

المؤلفون: Ragon, Brittany Knick, Shah, Mithun Vinod, D'Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., Usmani, Saad Z.

المصدر: Department of Medical Oncology Faculty Papers

مصطلحات موضوعية: adult, humans, United States, multiple myeloma, melphalan, neoplasms, second primary, transplantation, autologous, lenalidomide, hematologic neoplasms, Hematology, Medicine and Health Sciences, Oncology

الوصف: The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post-auto-HSCT.

وصف الملف: application/pdf

العلاقة: https://jdc.jefferson.edu/medoncfp/245Test; https://jdc.jefferson.edu/context/medoncfp/article/1245/viewcontent/REF_ID_4723.pdfTest; https://jdc.jefferson.edu/context/medoncfp/article/1245/filename/0/type/additional/viewcontent/Supplemental_Tables.pdfTest

الإتاحة: https://jdc.jefferson.edu/medoncfp/245Test
https://jdc.jefferson.edu/context/medoncfp/article/1245/viewcontent/REF_ID_4723.pdfTest
https://jdc.jefferson.edu/context/medoncfp/article/1245/filename/0/type/additional/viewcontent/Supplemental_Tables.pdfTest

المؤلفون: Walter, Angela Wangari, Lee, Ju‐Whei, Streck, Joanna M., Gareen, Ilana F., Herman, Benjamin A., Kircher, Sheetal M., Carlos, Ruth C., Kumar, Shaji K., Mayer, Ingrid A., Saba, Nabil F., Fenske, Timothy S., Neal, Joel W., Atkins, Michael B., Hodi, Frank S., Kyriakopoulos, Christos E., Tempany‐Afdhal, Clare M., Shanafelt, Tait D., Wagner, Lynne I., Land, Stephanie R., Ostroff, Jamie S., Park, Elyse R.

المساهمون: National Cancer Institute, National Institute on Drug Abuse

المصدر: Cancer ; volume 130, issue 3, page 439-452 ; ISSN 0008-543X 1097-0142

الوصف: Background Tobacco use is associated with adverse outcomes among patients diagnosed with cancer. Socioeconomic determinants influence access and utilization of tobacco treatment; little is known about the relationship between neighborhood socioeconomic disadvantage (NSD) and tobacco assessment, assistance, and cessation among patients diagnosed with cancer. Methods A modified Cancer Patient Tobacco Use Questionnaire (C‐TUQ) was administered to patients enrolled in nine ECOG‐ACRIN clinical trials. We examined associations of NSD with (1) smoking status, (2) receiving tobacco cessation assessment and support, and (3) cessation behaviors. NSD was classified by tertiles of the Area Deprivation Index. Associations between NSD and tobacco variables were evaluated using logistic regression. Results A total of 740 patients completing the C‐TUQ were 70% male, 94% White, 3% Hispanic, mean age 58.8 years. Cancer diagnoses included leukemia 263 (36%), lymphoma 141 (19%), prostate 131 (18%), breast 79 (11%), melanoma 69 (9%), myeloma 53 (7%), and head and neck 4 (0.5%). A total of 402 (54%) never smoked, 257 (35%) had formerly smoked, and 81 (11%) were currently smoking. Patients in high disadvantaged neighborhoods were approximately four times more likely to report current smoking (odds ratio [OR], 3.57; 95% CI, 1.69–7.54; p = .0009), and more likely to report being asked about smoking (OR, 4.24; 95% CI, 1.64–10.98; p = .0029), but less likely to report receiving counseling (OR, 0.11; 95% CI, 0.02–0.58; p = .0086) versus those in the least disadvantaged neighborhoods. Conclusions Greater neighborhood socioeconomic disadvantage was associated with smoking but less cessation support. Increased cessation support in cancer care is needed, particularly for patients from disadvantaged neighborhoods.

الإتاحة: https://doi.org/10.1002/cncr.35039Test

المؤلفون: Abdallah, Nadine H., Nagayama, Hiroki, Takahashi, Naoki, Gonsalves, Wilson, Fonder, Amie, Dispenzieri, Angela, Dingli, David, Buadi, Francis K., Lacy, Martha Q., Hobbs, Miriam, Gertz, Morie A., Binder, Moritz, Kapoor, Prashant, Warsame, Rahma, Hayman, Suzanne R., Kourelis, Taxiarchis, Hwa, Yi L., Lin, Yi, Kyle, Robert A., Rajkumar, S. Vincent, Broski, Stephen M., Kumar, Shaji K.

المصدر: Blood Cancer Journal ; volume 13, issue 1 ; ISSN 2044-5385

مصطلحات موضوعية: Oncology, Hematology

الوصف: Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this study was to evaluate the association between muscle and fat areas and radiodensity, and overall survival (OS) in patients with newly diagnosed MM. We included 341 patients diagnosed with MM from 2010–2019 who had an 18 F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis. A cross-sectional image at the third lumbar vertebrae was segmented into muscle and fat components. Median follow up was 5.7 years. There was no association between sarcopenia and baseline disease characteristics or OS. Low muscle radiodensity was associated with higher disease stage, anemia, and renal failure. OS was 5.6 vs. 9.0 years in patients with muscle radiodensity in the lower vs. middle/upper tertiles, respectively ( P = 0.02). High subcutaneous adipose tissue (SAT) radiodensity was associated with higher stage, anemia, thrombocytopenia, hypercalcemia, renal failure, and high LDH. OS was 5.4 years vs. not reached in patients with SAT radiodensity in the upper vs. middle/lower tertiles, respectively ( P = 0.001). In conclusion, sarcopenia was not associated with OS in MM patients. High SAT radiodensity and low muscle radiodensity were associated with advanced disease stage and adverse laboratory characteristics.

الإتاحة: https://doi.org/10.1038/s41408-023-00934-3Test
https://www.nature.com/articles/s41408-023-00934-3.pdfTest
https://www.nature.com/articles/s41408-023-00934-3Test